MDMarina A. Dzhavakhyan

Marina A. Dzhavakhyan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina A. Dzhavakhyan has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of the composition and technology of pastilles with eutectic extract of leaves of Bupleurum aureum L.

    by Vitaliya S. Dizik, Дизик Виталия Сергеевна, Marina A. Dzhavakhyan, Джавахян М. А., Elena I. Kalenikova, Каленикова Е. И.

    Background. The use of eutectic solvents, whose formation is driven by the creation of a supramolecular network of hydrogen bonds, enables highly efficient extraction of biologically active substances from plant materials. In previous studies, the authors obtained a eutectic extract from the leaves of Bupleurum aureum L. and demonstrated its gastroprotective activity. Aim. To develop a novel pharmaceutical form (pastilles) based on the highly effective eutectic extract of Bupleurum aureum L. The research focuses on substantiating the choice of an oral dosage form and selecting an optimal composition of excipients to ensure pleasant organoleptic properties, which is a strategic direction for improving patient compliance. Materials and methods. The previously obtained eutectic extract of Bupleurum aureum L. (rutin content – 1.493 mg / ml, chlorogenic acid – 0.716 mg / ml) was used as the active substance. Excipients: ethyl alcohol (96 %, GOST R 5962–2013, Russia), agar-agar 900 (E406) (S-Chief SFC-014, Russia), apple pectin (S-Chief SFC-015, Russia), medical gelatin (Xiamen Gelken Gelatin Co, China), sodium carboxymethylcellulose (TU 2231-034-79249837-2006), food-grade alginate (GOST 33310–2015), guar gum (GOST 33310–2015), xanthan gum (E415) (GOST 33310–2015), food-grade citric acid (GOST 908–2004), carnauba wax (E903) (GOST 33310–2015). Development of pastilles formulations with extract was conducted in accordance with the definitions and requirements of the Russian Pharmacopoeia. Results. Based on organoleptic characteristics, the optimal combination of base-forming components was selected – agar and pectin (2 % each). The concentration and type of moisture-retaining excipient were established by assessing the drying rate of experimental samples. Taste correctors and lozenge coating were selected using a modified method by A. I. Tenzova. Conclusion. An optimal formulation for pastilles based on the liquid eutectic extract of Bupleurum aureum L. has been developed, comprising agar, pectin, xanthan gum, glucose syrup, and citric acid. The developed composition ensures the stability of the dosage form and the correction of organoleptic properties to enhance patient compliance.

  • Relationships between classes of bioactive substances and medicinal properties of plants of the Abrau Peninsula: Mathematical approaches to assessment

    by Ilya V. Markin, Nikita A. Galkin, Marina A. Dzhavakhyan, Elena S. Shchelkanova, Nikolay B. Fadeev, Natalya V. Varlamova, Artur S. Baimashev

    Background. The work is devoted to the analysis of the pharmacological potential of the flora of the Abrau Peninsula based on data from scientific publications containing research results, indicating the relevant plants and the various biologically active substances they contain. Aim. Choosing the optimal mathematical approach to assessing the relationship between the classes of substances that make up plants growing on the territory of the Abrau Peninsula and their medicinal properties. Materials and methods. The relationship between the therapeutic properties of vascular plants and their chemical composition was investigated based on data collected from over 1 000 scientific publications. The analysis was performed using clustering methods and regression analysis. Conclusion. The conducted research has made it possible to form a database of vascular plants with medicinal properties, identify patterns between medicinal properties and the chemical composition of plants, and predict promising plant species based on these patterns. The results obtained can be used for further research in the field of phytochemistry and pharmacology, as well as for the development of new medicines based on plants of the Abrau Peninsula.

  • Open Access

    Features of pathological mechanisms of tooth damage in workers of chemical industries

    by A. V. Mitronin, A. M. Fulova, И. А. Иваньков, M. A. Dzhavakhyan, A. A. Prokopov

    INTRODUCTION. Under conditions of increasing exposure to chemical factors that predispose individuals to the development of pathology, the processes of hard-tooth-tissue destruction undergo modification not only in terms of their kinetics but also through the direct incorporation of exogenous chemical agents. These circumstances inevitably affect the macro- and microelement composition of enamel, as well as dentin and cementum in cases of disease progression. Obtaining reliable information on elemental composition is crucial for choosing appropriate treatment strategies and substantiating preventive measures. AIM. To perform X-ray fluorescence analysis of teeth from employees of chemical enterprises, assessing qualitative and quantitative changes in elemental composition associated with pathological processes. MATERIALS AND METHODS. The dental status of 100 workers and engineering personnel involved in the production of biologically active substances, paint-and-coating materials, and metal products, all of whom had direct contact with inorganic and organic reagents, was assessed. The control group included teeth from 50 individuals working at the same enterprises but not exposed to occupational hazards. The chemical composition of tooth hard-tissue samples was determined using an M4 TORNADO (Bruker) X-ray fluorescence spectrometer. The MultiPoint mode was used. The software provides the content of each element relative to the total amount of detected elements, considering the entire spectrum as 100%. A relatively constant Ca/P ratio served as an additional reference point for discussing deviations from normal values. RESULTS. The identified diseases in the affected zones were accompanied by atypical accumulations of trace elements detected via XRF spectra. In several employees of a metallurgical plant, high titanium content – up to 1.14 wt% of total elemental content – was found in areas of dental erosion. Titanium levels in adjacent intact enamel were significantly reduced, although trace amounts were still present. In patients with long-term employment at a paint, coating, and anti-corrosion materials enterprise, potassium content in deep carious lesions reached 12.64%, and most individuals also showed substantial levels of zinc, barium, iron, sulfur, chlorine, manganese, and copper. Among workers of an agrobiological enterprise without hot workshops or industrial dust – due to multistage air purification and sterilization – caries prevailed. In employees of a chemical-pharmaceutical production facility, no cases of caries were detected; only non-inflammatory conditions such as increased tooth wear and wedge-shaped defects were diagnosed. CONCLUSIONS. XRF analysis demonstrated that enamel demineralization processes in workers of chemical industries are accompanied by qualitative and quantitative changes in trace-element profiles within pathological zones. Environmental exposure results in the isomorphic and isoinic incorporation of elements into apatite structures of hard tooth tissues and disrupts the natural kinetics of mineralization and demineralization. The intensity of trace-element accumulation in tooth tissues is directly related to the degree of industrial air purification. Treatment and prevention of dental disorders in these workers must account for industry-specific occupational factors.


  • Open Access

    Original drugs approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2024

    by D. V. Kurkin, N. A. Osadchenko, A. R. Makarova, D. A. Galkina, D. A. Bakulin, O. V. Shatalova, A. V. Strygin, V. I. Petrov, O. V. Marincheva, Yu. V. Gorbunova, et al.

    The U.S. Food and Drug Administration (FDA), in particular the Center for Drug Evaluation and Research (CDER), plays a key role in ensuring the safety, efficacy, and innovation of medicines entering the U.S. market, and then the world. The annual review of new medicines approved by the FDA is an important tool for analyzing current trends in pharmacology and medicine, reflecting progress in the treatment of complex diseases, including cancers, orphan diseases, and infections. The review is compiled to familiarize medical specialists and pharmacologists with current trends in the registration of original medicines and in the therapy of malignant neoplasms, orphan diseases.The aim. To summarize and systematize data on the newest medicines that entered the market in 2024, as well as to analyze the mechanisms of their action. The article aims to inform medical specialists and pharmacologists about current trends in the development and registration of innovative medicines in 2024.Materials and methods. The presented data are taken from open sources and supplemented with the results of individual studies on new mechanisms and approaches in therapy. The main list of new drugs and introductory information about them are taken from the FDA report “Novel Drug Approvals for 2024”. Data on medicine prescriptions, as well as information on the mechanism of action, are taken from published summary of product characteristics (SmPC) published on this resource, as well as from the Drugs.com website. To describe previously registered medicines for which a new indication is presented, Drugs.com reports were also used. Structural formulas of drugs are taken from the PubChem resource. In case of the absence of structural formula, data from their SmPC or third-party resources, such as Drugbank, were used. The search for literature data on fundamental studies relating to the mechanisms of action of the presented medicines was carried out in the PubMed, ResearchGate, Google Scholar and elibrary.ru databases.Results. A statistical analysis of registrations, the dynamics of changes in the shares of various types of medicines and basic data on new original drugs registered by CDER are presented. In 2024, the FDA registered 50 original medicines, among which 48% contain a “first-in-class” molecule as an active substance. Small molecules include active substances — 60%, and biopharmaceuticals — 34% (the remaining 6% are imaging agents). At the same time, monoclonal antibodies (mAb) of antitumor and anti-inflammatory action occupy a larger share among biopharmaceuticals.Conclusion. The large proportion of biopharmaceuticals among those newly registered in 2024 emphasizes the dynamic development of the pharmaceutical industry and its focus on personalized medicine and biotechnology. Therapy based on mAbs interacting with receptors, as well as immunotherapy based on newly discovered mechanisms of antitumor immunity, occupies a separate part in the structure of registered original medicines. The search for new rational combinations of antibiotics remains relevant. Most of the original drug market is still made up of small molecules, among which there are medicines — ligands of new targets and oligonucleotide sequences.


  • Open Access

    Analysis of Russian pharmaceutical specialists labor market for 2019–2022

    by D. V. Kurkin, Yu. S. Knyazeva, O. V. Ivanova, Yu. A. Kolosov, Yu. V. Gorbunova, D. A. Bakulin, I. S. Krysanov, D. L. Klabukova, M. A. Javakhyan, V. I. Zvereva, et al.

    The higher education system is becoming more and more competitive every year. It faces ambitious tasks of training highly qualified personnel and ensuring technological sovereignty. A labor market analysis is an integral component of the early career guidance work with students and their navigation in the profession, which is especially important at the beginning of their employment.The aim of the work was to conduct a comparative analysis of supply and demand indicators in the labor market of pharmaceutical specialists in nine Russian regions in 2019–2022.Materials and methods. The research methodology included the collection, quantitative and qualitative analyses of the data on the SuperJob.ru website. The posted offers (vacancies) and CVs were analyzed on the portal SuperJob.ru (a large online service of CVs and vacancies from direct employers, agencies, employment centers) for 2019–2022 in nine regions and federal districts of Russia: Moscow and the Moscow region, St. Petersburg and the Leningrad region, the Central Federal District (without the Moscow region), the Northwestern Federal District (without the Leningrad Region), the Volga Federal District, the Urals Federal District, the Siberian Federal District, the Far Eastern Federal District, the Southern and North Caucasus Federal Districts.Results. The analysis of the number of posted vacancies and CVs in the recruitment agency database for 2019–2022 shows a stable shortage of pharmacy professionals with both secondary (vacancies / CVs – 42112 / 41037) and higher professional education (vacancies / CVs – 36432 / 25149). The pointed out specialists are among the most required ones by employers, and pharmacy is one of the most popular areas for candidates. Cities with a high level of economy and population experience a greater deficit in specialists with pharmaceutical education. Salary levels of specialists with higher or secondary education are almost comparable on average from 50 to 75 thousand rubles, but employers generally prefer to hire specialists with higher education.Conclusion. On average in the regions, the demand for specialists with higher education is lower than the demand for specialists with secondary education and the salary expectations of pharmacists coincide with the employers’ offers, while the salary expectations of specialists with higher education are higher in the market. Specialists with secondary education are much more numerous, as they are trained by a much larger number of educational institutions. For pharmacy technicians, a pharmacy is often the only place of work in their specialty, while for pharmacists it is usually a starting point.


  • Талидомид: история исследования и перспективы медицинского применения (обзор)

    by Денис Владимирович Куркин, Дмитрий Александрович Бакулин, Евгений Игоревич Морковин, Иван Сергеевич Крысанов, Екатерина Владимировна Макарова, Анна Павловна Цаплина, Дарья Леонидовна Клабукова, Ольга Викторовна Иванова, Юлия Васильевна Горбунова, Марина Аркадьевна Джавахян, et al.

    Талидомид применялся в 1950-х гг. в качестве седативного средства. Из-за выраженной тератогенности он был удален с рынка в 1960-х гг., а 40 лет спустя возвращен в клинику как противоопухолевое средство. Сейчас талидомид и его производные (IMiDs и CELMoDs) активно применяются для лечения некоторых гематологических опухолей. Спектр его свойств включает иммуномодулирующее, противовоспалительное и антиангиогенное действие, отмечается нейропротекторный и анальгетический потенциал. Талидомид взаимодействует с компонентом убиквитин-лигазного комплекса (белок цереблон), меняя его специфичность, что приводит к протеасомной деградации ряда неосубстратов, в том числе факторов транскрипции, важных для эмбрионального развития (SALL4, p63, PLZF), ключевых для гематологических опухолей (Ikaros, Aiolos, CK1α и др.) и регулирующих экспрессию мРНК ФНО-α. Раскрытие мишени способствовало быстрому развитию технологии PROTAC в рамках поиска способа внутриклеточной деградации целевых белков. В работе описаны некоторые исследования, посвященные современному применению талидомида и его аналогов.

  • Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders

    by D.V. Kurkin, E.I. Morkovin, D.A. Bakulin, Yu.V. Gorbunova, O.V. Ivanova, E.V. Pavlova, V.I. Zvereva, M.A. Dzhavakhyan, I.S. Krysanov, Yu.A. Kolosov, et al.

    Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.

  • Open Access

    Physiology and pharmacology of glucagon-like peptide-1 receptor

    by D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, et al.

    Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight the importance of glucagon-like peptide-1 (GLP-1) receptor agonists in the pharmacotherapy structure.The aim of the work was to review the literature regarding the physiology of GLP-1 and the therapeutic potential and development trends of its agonists.Materials and methods. The search for the review materials was carried out using the abstract databases of PubMed, Google Scholar and e-Library. The search was carried out for publications from 2000 to 2023, using the following keywords: “GLP-1”; “GLP-1R agonists”; “GIP”; “exenatide”; “liraglutide”; “dulaglutide”; “semaglutide”; “lixisenatide”; “albiglutide”; “taspoglutide” taking into account various spellings.Results. The interaction of almost all food components with enteroendocrine cells of the intestine leads to the secretion of incretins (primarily GLP-1) into the blood, triggering a complex of physiological reactions aimed primarily at the rapid utilization of incoming glucose (regulation of insulin and glucagon secretion), as well as the central regulation of dietary behavior (slowing gastric emptying and the formation of a feeling of satiety). A wide distribution of the GLP-1 receptor in various tissues and organs, its connection with intracellular signaling cascades aimed at launching energy-consuming remodeling (recovery) processes in endothelial cells, heart, neurons, beta cells, etc., is the basis for a wide range of pleiotropic effects of GLP-1 unrelated to its hypoglycemic effect. The discovery of synthetic GLP-1 receptor agonists with a long period of action has made it possible not only to therapeutically influence various parts of carbohydrate metabolism disorders, but also to increase the functional reserves of the target diabetes organs, reducing the risk of developing complications of the disease. Incretin-like drugs are well tolerated, with nausea being the most common side effect. The factors limiting a wider use of the drugs include their high cost and the preferred form of a subcutaneous solution. The current research is focused on the development of long-acting, oral, dual and triple agonists, fixed-dose combinations, and small molecule drugs.Conclusion. GLP-1 receptor agonists are a class of effective and safe drugs for the treatment of diabetes and obesity, which is rapidly developing in the most advanced areas of pharmacy. A further development of this group and the solution of the identified problems will open up new opportunities for the treatment of diabetes and its complications.


  • Open Access

    Investigating the current state of the Russian market for drugs treating infectious and inflammatory conditions of oral cavity and oropharynx to demonstrate the need for new drug development

    by V. I. Zvereva, D. R. Dzhavakhyan, V. N. Dul, V. S. Bobyleva, A. A. Markaryan, E. I. Morkovin, D. V. Kurkin, M. A. Dzhavakhyan

    Objective: to assess the relevance and commercial prospects of bringing to market a drug for the local treatment of infectious and inflammatory diseases of oral cavity and oropharynx.Material and methods. The objects of the study were the drug nomenclatures in the State Register of Medicines, the Register of Medicines of Russia, as well as data from the Federal Service for Surveillance in Healthcare. The analysis of scientific publications in the field of marketing research of drugs, found in eLibrary.ru and PubMed/MEDLINE databases was carried out. For analyzing the structure and marketing research of drugs in the study group, specific methods of information retrieval, content analysis, description, data aggregation, ranking, data grouping method, system approach, as well as such methods of marketing analysis as determining the breadth and depth of the assortment, the renewal index, the vital importance index, SWOT analysis (strengths, weaknesses, opportunities, threats) were used.Results. The assortment of drugs for the local treatment of oral cavity and oropharyngeal infectious and inflammatory diseases was structured by the nature of the active substance, type of dosage form, and country of origin. The main trends in the development of the market of drugs of this group were identified. An analysis of the range of drugs using marketing research methods made it possible to establish the breadth and completeness of the range. The calculated renewal and vitality indices confirmed the relevance of developing new drugs with the considered pharmacotherapeutic action.Conclusion. The study revealed the main trends in the development of the market of drugs of the action in question. The SWOT analysis showed a possible strategy for developing and launching a new drug on the market.


  • Open Access

    Overview of drugs approved by the FDA in 2022

    by D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, Yu. V. Gorbunova, Yu. A. Kolosov, M. A. Dzhavakhyan, I. E. Makarenko, R. V. Drai, А. В. Заборовский, O. V. Shatalova, et al.

    The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were utilized. The search was conducted for the publications spanning the period from 2008 to 2023. Herewith, the following keywords and word combinations were used: new drug approval, NDA, drug authorization, approval package, breakthrough medicine.Results. The discovery and development of medications are among the most crucial scientific processes in healthcare. Developing a new drug is a highly intricate, expensive, and time-consuming process. Nowadays, the problem of costs reduction and the process of expedited discovering of new medications are particularly pertinent. To optimize the search for active compounds, virtual and high-throughput screenings, machine learning, artificial intelligence, cryo-electron microscopy, and drug repurposing are employed. Simultaneously, the search for original molecules to serve as the basis for innovative drugs continues. This article presents a review of medications approved by the FDA in 2022 for the treatment of various pathologies.Conclusion. A drug development is a complex and resource-intensive process, with only a small fraction of candidates advancing to clinical trials. A drug design evolves in tandem with societal needs, and this review highlights some of the medications approved by the FDA in 2022. Technological advancements are expected to expedite drug development, potentially reducing the time to the market. Biotechnology, including cell therapy, holds significant prospects, and achievements in genetic mapping and chip technologies will enhance the accessibility of personalized pharmacology.